Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase
Thomas Checkouri,Gaspard Gerschenfeld,Pierre Seners,Marion Yger,Wagih Ben Hassen,Nicolas Chausson,Stéphane Olindo,Jildaz Caroff,Gaultier Marnat,Frédéric Clarençon,Jean-Claude Baron,Guillaume Turc,Sonia Alamowitch,Caroline Arquizan,Yves Berthezene,Grégoire Boulouis,Serge Bracard,Nicolas Bricout,Tae-Hee Cho,Arturo Consoli,Vincent Costalat,Jean-Philippe Cottier,Séverine Debiais,Benjamin Gory,Hilde Henon,Bertrand Lapergue,Michael Obadia,Catherine Oppenheim,Fernando Pico,Michel Piotin,Sébastien Richard,Mathieu Zuber,Clémence Blanc,David Calvet,Christian Denier,Sam Ghazanfari,Erwah Kalsoum,Yann L’Hermitte,Laurence Legrand,Jean-Sebastien Liegey,Malgorzata Milnerowicz,Olivier Naggara,Mathilde Poli,Kévin Premat,Igor Sibon,Candice Sabben,Eimad Shotar,Didier Smadja,Laurent Spelle,Thomas CheckouriGaspard GerschenfeldPierre SenersMarion YgerWagih Ben HassenNicolas ChaussonStéphane OlindoJildaz CaroffGaultier MarnatFrédéric ClarençonJean-Claude BaronGuillaume TurcSonia AlamowitchAP-HP,Service des Urgences Cérébro-Vasculaires,Hôpital Pitié-Salpêtrière,Hôpital Saint-Antoine,Sorbonne Université,Paris,France (T.C.,G.G.,M.Y.,S.A.).STARE team,iCRIN,Institut du Cerveau et de la Moelle épinière,ICM,Paris,France (T.C.,G.G.,M.Y.,S.A.).Service de Neurologie,GHU Paris Psychiatrie et Neurosciences,France (P.S.).Université de Paris,INSERM U1266,FHU Neurovasc,France (P.S.,W.B.H.,N.C.,J.-C.B.,G.T.).Service de Neurologie,Hôpital Fondation Rothschild,Paris,France (P.S.).Service de Neuroradiologie,GHU Paris Psychiatrie et Neurosciences,France (W.B.H.).Service de Neurologie,Unité Neuro-vasculaire,Hôpital Sud Francilien,Corbeil-Essonnes (N.C.).Service de Neurologie Vasculaire (S.O.)Service de Neuroradiologie diagnostique et interventionnelle (G.M.)CHU de Bordeaux,France (G.M.).AP-HP,Service de Neuroradiologie interventionnelle (NEURI),Hôpital Bicêtre,Université Paris-Saclay,Le Kremlin-Bicêtre,France (J.C.).AP-HP,Service de Neuroradiologie,Hôpital Pitié-Salpêtrière,Sorbonne Université,Paris,France (F.C.).,on behalf of the TETRIS and PREDICT-RECANAL Collaborators
Caroline Arquizan
Yves Berthezene
Grégoire Boulouis
Serge Bracard
Nicolas Bricout
Tae-Hee Cho
Arturo Consoli
Vincent Costalat
Jean-Philippe Cottier
Séverine Debiais
Benjamin Gory
Hilde Henon
Bertrand Lapergue
Michael Obadia
Catherine Oppenheim
Fernando Pico
Michel Piotin
Sébastien Richard
Mathieu Zuber
Clémence Blanc
David Calvet
Christian Denier
Sam Ghazanfari
Erwah Kalsoum
Yann L'Hermitte
Laurence Legrand
Jean-Sebastien Liegey
Malgorzata Milnerowicz
Olivier Naggara
Mathilde Poli
Kévin Premat
Igor Sibon
Candice Sabben
Eimad Shotar
Didier Smadja
Laurent Spelle
DOI: https://doi.org/10.1161/STROKEAHA.123.042691
IF: 10.17
2023-08-26
Stroke
Abstract:Stroke, Ahead of Print. BACKGROUND:Intravenous thrombolysis (IVT) with alteplase or tenecteplase before mechanical thrombectomy is the recommended treatment for large-vessel occlusion acute ischemic stroke. There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before mechanical thrombectomy, and little data on their potential differences stratified by ER predictors such as IVT to ER evaluation (IVT-to-EReval) time, occlusion site and thrombus length.METHODS:We retrospectively compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation large-vessel occlusion acute ischemic stroke patients from the PREDICT-RECANAL (alteplase) and Tenecteplase Treatment in Ischemic Stroke (tenecteplase) French multicenter registries. ER was defined as a modified Thrombolysis in Cerebral Infartion score 2b-3 on the first angiographic run, or noninvasive vascular imaging in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (leading to exact balance in patient history, stroke characteristics, and initial management between groups) and confirmed with adjusted logistic regression (sensitivity analysis). A stratified analysis based on pre-established ER predictors (IVT-to-ERevaltime, occlusion site, and thrombus length) was conducted.RESULTS:Overall, 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95% CI, 0.83–1.44];P=0.52). A differential effect of tenecteplase versus alteplase on the probability of ER according to thrombus length was observed (Pinteraction=0.003), with tenecteplase being associated with higher odds of ER in thrombi >10 mm (odds ratio, 2.43 [95% CI, 1.02–5.81];P=0.04). There was no differential effect of tenecteplase versus alteplase on the likelihood of ER according to the IVT-to-ERevaltime (Pinteraction=0.40) or occlusion site (Pinteraction=0.80).CONCLUSIONS:Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-ERevaltime and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.
peripheral vascular disease,clinical neurology